Lv Donglai, Lu Lin, Hu Zongtao, Fei Zhenle, Liu Meiqin, Wei Lei, Xu Jun
Clinical Oncology Center, The 105 Hospital of The People's Liberation Army, 424 Changjiang West Road, Hefei, Anhui, China.
Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University, Chongqing, China.
Mol Neurobiol. 2017 Jan;54(1):727-735. doi: 10.1007/s12035-016-9689-5. Epub 2016 Jan 14.
Nestin has been identified as a molecular marker of neural progenitor cells and putative glioma stem cells (GSCs). Various studies examining the relationship between nestin expression with the clinical outcome in glioma patients have yielded inconclusive results. Thus, we conducted a systematic review to evaluate the association of nestin with prognosis and clinicopathological features of glioma patients. The electronic searches were performed through the database of PubMed, MEDLINE, Embase, and CNKI. In total, this meta-analysis included 14 studies covering 897 nestin + cases and 704 controls. The correlation between nestin expression and clinicopathological or prognostic parameters was evaluated by Stata 11.0 software. Our results showed that nestin protein abundance was significantly correlated with the histological grade [odds ratio (OR) = 4.36, 95 % confidence interval (CI) = 2.14-8.88, P = 0.003] of glioma. With respect to prognosis, nestin expression was positively correlated with overall survival (OS) [hazard ratio (HR) = 1.98, 95 % CI = 1.30-3.02, P = 0.000] and progression-free survival (PFS) (HR = 1.90, 95 % CI = 1.18-3.07, P = 0.040). The further stratified analysis not only defined the predictive function of nestin in different ages but also revealed that different antibodies did not alter the positive outcomes and higher standard cutoff values were more suitable for the accurate assay of nestin. Taken together, our results indicate that nestin may play an important role in the prediction of the clinicopathology and poor prognosis of glioma patients. This study should be taken into consideration in the development of new diagnostic and therapeutic programs.
巢蛋白已被确定为神经祖细胞和假定的胶质瘤干细胞（GSCs）的分子标志物。多项研究探讨巢蛋白表达与胶质瘤患者临床结局之间的关系，但结果尚无定论。因此，我们进行了一项系统评价，以评估巢蛋白与胶质瘤患者预后及临床病理特征的相关性。通过PubMed、MEDLINE、Embase和中国知网数据库进行电子检索。本荟萃分析共纳入14项研究，涵盖897例巢蛋白阳性病例和704例对照。采用Stata 11.0软件评估巢蛋白表达与临床病理或预后参数之间的相关性。我们的结果显示，巢蛋白的蛋白丰度与胶质瘤的组织学分级显著相关[比值比（OR）=4.36，95%置信区间（CI）=2.14 - 8.88，P = 0.003]。关于预后，巢蛋白表达与总生存期（OS）呈正相关[风险比（HR）=1.98，95%CI = 1.30 - 3.02，P = 0.000]和无进展生存期（PFS）（HR = 1.90，95%CI = 1.18 - 3.07，P = 0.040）。进一步的分层分析不仅明确了巢蛋白在不同年龄组中的预测功能，还表明不同抗体并未改变阳性结果，且更高的标准临界值更适合准确检测巢蛋白。综上所述，我们的结果表明巢蛋白可能在预测胶质瘤患者的临床病理和不良预后中发挥重要作用。在制定新的诊断和治疗方案时应考虑本研究结果。
